AbbVie completes $10.9 billion Apogee acquisition
AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics and reaffirmed 2026 adjusted diluted EPS guidance.
AbbVie completed the $10.9 billion acquisition of Apogee Therapeutics and reaffirmed its 2026 adjusted diluted EPS guidance. Original SEC Filing: AbbVie Inc. [ ABBV ] - 8-K - Sep. 03, 2026